ArticleNature2010
Immunology and the elusive AIDS vaccine.
Article in Nature, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls.PLoS pathogens · 2013Pooled it
- Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.The Lancet. Infectious diseases · 2012Trial
- A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.PloS one · 2011Trial
- Chemoenzymatic Synthesis and Antibody Binding of HIV-1 V1/V2 Glycopeptide-Bacteriophage QInternational journal of molecular sciences · 2021Article
- Persistent lentivirus infection induces early myeloid suppressor cells expansion to subvert protective memory CD8 T cell responseEBioMedicine · 2020Article
- Synergistic inhibition of cell-to-cell HIV-1 infection by combinations of single chain variable fragments and fusion inhibitors.Biochemistry and biophysics reports · 2019Article
- Article
- High-level expression of the HIV entry inhibitor griffithsin from the plastid genome and retention of biological activity in dried tobacco leaves.Plant molecular biology · 2018Article
- Article
- Tackling HIV and AIDS: contributions by non-human primate models.Lab animal · 2017Article
- Complex Subtype Diversity of HIV-1 Among Drug Users in Major Kenyan Cities.AIDS research and human retroviruses · 2017Article
- Interference of retroviral envelope with vaccine-induced CD8Retrovirology · 2017Article
- Article
- A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens.Frontiers in immunology · 2017Article
- Dendritic Cell Targeting Effectively Boosts T Cell Responses Elicited by an HIV Multiepitope DNA Vaccine.Frontiers in immunology · 2017Article
- Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory.International journal of molecular sciences · 2016Review
- Determination of the Membrane Permeability to Water of Human Vaginal Mucosal Immune Cells at Subzero Temperatures Using Differential Scanning Calorimetry.Biopreservation and biobanking · 2016Article
- Autoimmunity and dysmetabolism of human acquired immunodeficiency syndrome.Immunologic research · 2016Review
- A study of the osmotic characteristics, water permeability, and cryoprotectant permeability of human vaginal immune cells.Cryobiology · 2016Article
- A Critical Role of IL-21-Induced BATF in Sustaining CD8-T-Cell-Mediated Chronic Viral Control.Cell reports · 2015Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing a human immunodeficiency virus (HIV) vaccine is critical to end the global acquired immunodeficiency syndrome (AIDS) epidemic, but many question whether this goal is achievable. Natural immunity is not protective, and despite immunogenicity of HIV vaccine candidates, human trials have exclusively yielded disappointing results. Nevertheless, there is an indication that success may be possible, but this will be dependent on understanding the antiviral immune response in unprecedented depth to identify and engineer the types of immunity required. Here we outline fundamental immunological questions that need to be answered to develop a protective HIV vaccine, and the immediate need to harness a much broader scientific community to achieve this goal.
Indexed as
Identifiers
20220841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.